CTC-based assays are expected to be integrated into clinical blood panels as tumor markers with greater clinical utility than traditional markers such as CEA, CA19-9, or CA15-3, thereby supporting oncologists in therapeutic decision-making. This evidence concerns the gene CEACAM5 and neoplasm.